Its role Owner
Eli Lilly and Company (Lilly; NYSE: LLY) is a U.S.-based global pharmaceutical manufacturer that discovers, develops, and produces medicines for human health. Founded in 1876 and headquartered in Indianapolis, Indiana, the company’s portfolio spans small‑molecule and biologic therapies, with core focus areas including diabetes and metabolic diseases, immunology, oncology, and neuroscience.
Across the chemicals and life‑sciences value chain, Lilly operates extensive R&D and manufacturing networks for active pharmaceutical ingredients (APIs), biologics, and sterile injectable formulations, supported by global quality, regulatory, and supply‑chain systems. The company also develops drug‑delivery devices and collaborates with academic and industry partners to advance new therapeutic modalities.
Also known as Eli Lilly, Lilly USA, LLY, and Eli Lilly USA, LLC.
chemXplore tracks 6 projects involving Lilly, of which 4 are active.
Besides these 4, the record holds 2 completed projects.
Closest to start-up first.
The 2 that are completed, on hold or cancelled are in the record. See all 6 in chemXplore →
The dates themselves, per project, are for subscribers.
Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.
EBGLYSS shows durable control, less maintenance dosing and reduced topical use; TOGETHER‑PsO biomarker data assess Taltz+Zepbound vs Taltz; Olumiant pediatric alopecia areata results also included.
FDA clears pirtobrutinib for newly diagnosed CLL/SLL patients without 17p deletion after BRUIN CLL-313 showed a large PFS benefit versus bendamustine–rituximab.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.
Rapid, significant relief in skin clearance, itch, pain and patient satisfaction versus placebo; consistent safety and fewer patients required rescue medication.
Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
